ライフサイエンスコーパス: anaplastic

1 ht desmoplastic-nodular, two large cell, one anaplastic), 17 ependymomas (13 World Health Organizatio

2 ty tuned CAR T cells against newly diagnosed anaplastic and refractory or recurrent thyroid cancers.

3 s 4.5% (42% papillary, 42% follicular and 8% anaplastic), and the yield of malignancy decreased consi

4 Nine atypical, three anaplastic, and 39 typical meningiomas were retrospectiv

5 are subtypes of thyroid cancer-medullary and anaplastic-are ideally treated by physicians with experi

6 both IDH-mt and 1p/19q co-deletion, whereas anaplastic astrocytoma is divided into IDH wild-type ( I

7 Anaplastic astrocytoma samples with mutated IDH1 display

8 n levels were significantly higher in GB and anaplastic astrocytoma tissues than in grade II glioma a

9 erms glioblastoma, glioma, malignant glioma, anaplastic astrocytoma, anaplastic oligodendroglioma, an

10 tomas, 1 anaplastic oligodendroglioma, and 1 anaplastic astrocytoma.

11 ocytoma (IMA) cell line from a WHO grade III anaplastic astrocytoma.

12 rbations that yield high-grade astrocytomas (anaplastic astrocytomas and GBMs).

13 om World Health Organization (WHO) grade III anaplastic astrocytomas to WHO grade IV glioblastomas.

14 ls) were included (5 diffuse astrocytomas, 2 anaplastic astrocytomas, 5 gliomatosis cerebri, and 1 gl

15 Methods: Papillary (BcPAP) and anaplastic (CAL62 and FRO82-1) thyroid carcinoma cell li

16 cell cancer of the right lung (microcellular anaplastic carcinoma), was admitted with focal neurologi

17 was associated with aggressive medullary and anaplastic carcinomas, and its expression pattern in med

18 -expression profile is enriched in advanced, anaplastic, castration-resistant and metastatic prostate

19 27 trimethylation, is overexpressed in CD30+ anaplastic cells in primary cutaneous anaplastic T-cell

20 roliferation, and led to retinoblastoma with anaplastic changes.

21 en deletion show increased proliferation and anaplastic dedifferentiation, as well as mTORC1 hyperact

22 died from a secondary tumour (head and neck anaplastic embryonal rhabdomyosarcoma), all patients wer

23 reased OEF (+18%, P < .001, n = 20), whereas anaplastic glioma (WHO grade III) and glioblastoma (WHO

24 reation of a timely diagnostic algorithm for anaplastic glioma based on multivariable analysis of con

25 e undergone malignant progression (MP) to an anaplastic glioma or secondary glioblastoma (GBM).

26 older and had newly diagnosed non-co-deleted anaplastic glioma with WHO performance status scores of

27 patients with newly diagnosed non-co-deleted anaplastic glioma.

28 apy in newly diagnosed 1p/19q non-co-deleted anaplastic gliomas, which are associated with lower sens

29 w-grade fibrillary astrocytoma to high-grade anaplastic gliomas.

30 t temozolomide in adults with non-co-deleted anaplastic gliomas.

31 t side of her vision, due to a WHO grade III anaplastic haemangiopericytoma compressing the optic chi

32 Of the 6 patients who died, 5 had diffuse anaplastic histology.

33 itors induced tumors exhibiting a large-cell/anaplastic histopathology adjacent to the fourth ventric

34 carcinoma tissue specimens, particularly the anaplastic histotype, thyroid cancer cell lines, and rod

35 vasion and contributes to the oncogenesis of anaplastic large cell lymphoma (ALCL) are not completely

36 olesterol auxotrophy, particularly in ALK(+) anaplastic large cell lymphoma (ALCL) cell lines and pri

37 We used various ALK-positive anaplastic large cell lymphoma (ALCL) cell lines to eval

38 normal and malignant lymphocytes, including anaplastic large cell lymphoma (ALCL) cells.

39 WASP and WIP is frequently low or absent in anaplastic large cell lymphoma (ALCL) compared to other

40 onal antibodies in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) has had profound c

41 Anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma (ALCL) is a CD30-positive

42 Anaplastic large cell lymphoma (ALCL) is a distinct enti

43 Anaplastic large cell lymphoma (ALCL) is a mature T cell

44 Anaplastic large cell lymphoma (ALCL) is a mature T-cell

45 Anaplastic large cell lymphoma (ALCL) is a peripheral T-

46 Systemic anaplastic large cell lymphoma (ALCL) is an aggressive C

47 Systemic anaplastic large cell lymphoma (ALCL) is an aggressive T

48 Anaplastic large cell lymphoma (ALCL) is the most common

49 ntified in a subset of T-cell lymphomas with anaplastic large cell lymphoma (ALCL) morphology (ALK+ A

50 In ALK-rearranged anaplastic large cell lymphoma (ALCL), a specific subtyp

51 s with relapsed or refractory (R/R) systemic anaplastic large cell lymphoma (ALCL).

52 nd anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma (ALK-negative), despite t

53 events involved in breast implant-associated anaplastic large cell lymphoma (BI-ALCL) remain elusive.

54 incidence rate of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) at a high-volu

55 Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a very rare

56 Though rare, breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a CD30+ T-cel

57 Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a rare periph

58 Breast implant-associated anaplastic large cell lymphoma (breast implant ALCL) is

59 plastic lymphoma kinase (NPM-ALK) expressing anaplastic large cell lymphoma are not completely unders

60 chromosome breaks and translocations in the anaplastic large cell lymphoma breakpoint regions of NPM

61 ymphoma kinase (ALK)-positive and -negative, anaplastic large cell lymphoma cell lines and primary pa

62 optotic anaplastic lymphoma kinase-positive, anaplastic large cell lymphoma cell lines and that ectop

63 Breast implant-associated anaplastic large cell lymphoma is a rare cancer in patie

64 nerated to target different receptors on the anaplastic large cell lymphoma line L-82, but delivered

65 rmed mycosis fungoides (T-MF), and cutaneous anaplastic large cell lymphoma were studied in parallel

66 -cell lymphomas (targeting 75% with systemic anaplastic large cell lymphoma) were randomly assigned 1

67 xcluding anaplastic lymphoma kinase-positive anaplastic large cell lymphoma), upfront auto-SCT was as

68 ma kinase (ALK)-positive and 48 ALK-negative anaplastic large cell lymphoma, 14 adult T-cell leukemia

69 phomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma, and borderline cases.

70 sed or refractory Hodgkin lymphoma, systemic anaplastic large cell lymphoma, relapsed or refractory B

71 oides, Sezary syndrome, or primary cutaneous anaplastic large cell lymphoma, with disease progression

72 dvances made for patients with CD30-positive anaplastic large cell lymphoma.

73 phase 2 trials in CD30+ Hodgkin lymphoma and anaplastic large cell lymphoma.

74 es, including classical Hodgkin lymphoma and anaplastic large cell lymphoma.

75 dominant genetic lesion underlying pediatric anaplastic large cell lymphomas (ALCL) and inflammatory

76 ung cancers (NSCLC) and approximately 70% of anaplastic large cell lymphomas (ALCL).

77 ncluding anaplastic lymphoma kinase (ALK)(-) anaplastic large cell lymphomas (ALCLs).

78 for anaplastic lymphoma kinase (ALK)- nodal anaplastic large cell lymphomas (ALCLs; n = 24) were obt

79 e treatment of relapsed Hodgkin and systemic anaplastic large cell lymphomas--both characterized by h

80 n of tumors indistinguishable from patients' anaplastic large cell lymphomas.

81 30-expressing Classical Hodgkin and systemic anaplastic large cell lymphomas.

82 tric inflammatory myofibroblastic tumors and anaplastic large cell lymphomas.

83 l characteristics of primary patient-derived anaplastic large cell lymphomas.

84 lymphoma cell lines, including mantle cell, anaplastic large cell, and Hodgkin lymphoma cell lines.

85 T cell not otherwise specified; 2 (13%) had anaplastic large cell; and 1 each had extranodal natural

86 T-cell lymphoma, characterized by the CD30+ anaplastic large T cells, comprises the second most comm

87 d, refractory Hodgkin lymphomas and systemic anaplastic large T-cell lymphomas.

88 apy-sensitive disease (86% v 60%; P < .001), anaplastic large-cell histology (53% v 40%; P = .04), an

89 defining events in several tumors, including anaplastic large-cell lymphoma (ALCL) and non-small cell

90 lastic lymphoma kinase-positive (NPM-ALK(+)) anaplastic large-cell lymphoma (ALCL) as model system, w

91 Most of the anaplastic large-cell lymphoma (ALCL) cases carry the t(

92 Anaplastic large-cell lymphoma (ALCL) is a clinical and

93 Breast implant-associated anaplastic large-cell lymphoma (ALCL) is a recently desc

94 Systemic anaplastic large-cell lymphoma (ALCL) is a T-cell lympho

95 o in the hematologic malignancy ALK-positive anaplastic large-cell lymphoma (ALCL) resistant to ALK-s

96 and is downregulated in T-lymphomas, such as anaplastic large-cell lymphoma (ALCL) tumors.

97 Anaplastic lymphoma kinase (ALK) -positive anaplastic large-cell lymphoma (ALCL) was excluded.

98 t of patients with Hodgkin lymphoma (HL) and anaplastic large-cell lymphoma (ALCL), the study by Jaco

99 th anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphoma (ALCL).

100 Breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) is a CD30-posi

101 7), adult T-cell lymphoma/leukemia (n = 4), anaplastic large-cell lymphoma (n = 2), and extranodal n

102 gioimmunoblastic T-cell lymphoma [AITL], and anaplastic large-cell lymphoma [ALCL]) is difficult, wit

103 All seven patients without anaplastic large-cell lymphoma achieved CR.

104 harbouring ALK translocations, particularly anaplastic large-cell lymphoma and inflammatory myofibro

105 e aberrantly expressed in a subset of T-cell anaplastic large-cell lymphoma and non-small-cell lung c

106 e treatment of relapsed Hodgkin lymphoma and anaplastic large-cell lymphoma by the Food and Drug Admi

107 th of a subset of acute myeloid leukemia and anaplastic large-cell lymphoma cell lines by inducing ce

108 for select patients, particularly those with anaplastic large-cell lymphoma histology.

109 In T-cell lymphomas, anaplastic large-cell lymphoma is defined by mutually ex

110 itive mycosis fungoides or primary cutaneous anaplastic large-cell lymphoma who had been previously t

111 RC1; and expression of CD30 (the hallmark of anaplastic large-cell lymphoma) and of immunosuppressive

112 NMT1 and expression of CD30 (the hallmark of anaplastic large-cell lymphoma).

113 Outcomes of 241 patients (112 anaplastic large-cell lymphoma, 102 peripheral T-cell ly

114 of PTCL not otherwise specified (PTCL-NOS), anaplastic large-cell lymphoma, and adult T-cell leukemi

115 We also examine T-cell lymphomas, including anaplastic large-cell lymphoma, angioimmunoblastic T-cel

116 In contrast to Hodgkin lymphoma and systemic anaplastic large-cell lymphoma, CD30 expression of malig

117 lifications, or oncogenic mutations, such as anaplastic large-cell lymphoma, inflammatory myofibrobla

118 tivating ALK aberrations (eight of nine with anaplastic large-cell lymphoma, one of 11 with neuroblas

119 urable or evaluable solid or CNS tumours, or anaplastic large-cell lymphoma, refractory to therapy an

120 target in patients with Hodgkin lymphoma and anaplastic large-cell lymphoma.

121 n children with refractory solid tumours and anaplastic large-cell lymphoma.

122 ne marrow and blood samples of patients with anaplastic large-cell lymphoma.

123 a (ENKCL), and ATLL and a lower incidence of anaplastic large-cell lymphoma; Hispanics had a higher i

124 Anaplastic large-cell lymphomas (ALCLs) bearing the t(2;

125 Anaplastic large-cell lymphomas (ALCLs) encompass at lea

126 K+ xenografts in mice, including Karpas-299 (anaplastic large-cell lymphomas [ALCL]) and H3122 (NSCLC

127 In addition to 100% anaplastic large-cell lymphomas, 57% of other PTCL entit

128 n of tumors indistinguishable from patients' anaplastic large-cell lymphomas.

129 ophenotype characteristic of patient-derived anaplastic large-cell lymphomas.

130 atients with relapsed or refractory systemic anaplastic large-T-cell lymphoma who previously received

131 relapsed or refractory Hodgkin's lymphoma or anaplastic large-T-cell lymphoma, had biopsy-proven CD30

132 elapsed or refractory Hodgkin's lymphoma and anaplastic large-T-cell lymphoma.

133 %] with Hodgkin's lymphoma and one [2%] with anaplastic large-T-cell lymphoma; 28 [43%] during phase

134 osis of breast implant-associated large cell anaplastic lymphoma for their repercussions.

135 Anaplastic lymphoma kinase (ALK) -positive anaplastic la

136 Concomitant inhibition of anaplastic lymphoma kinase (ALK) and bromodomain-4 (BRD4

137 Anaplastic lymphoma kinase (Alk) and leucocyte tyrosine

138 We discovered anaplastic lymphoma kinase (ALK) as a candidate thinness

139 t inhibitors of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) blocked D2R desensitiza

140 The phylogenetic proximity of the ROS1 and anaplastic lymphoma kinase (ALK) catalytic domains led t

141 Anaplastic lymphoma kinase (ALK) constitutes a part of t

142 epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) define two unique subty

143 lymphoma (ALCL) is a T-cell lymphoma, whose anaplastic lymphoma kinase (ALK) expression varies accor

144 distinguished by the presence or absence of anaplastic lymphoma kinase (ALK) expression.

145 Rearrangements involving the anaplastic lymphoma kinase (ALK) gene are defining event

146 d here to detection of rearrangements in the anaplastic lymphoma kinase (ALK) gene associated with AL

147 he discovery of rearrangements involving the anaplastic lymphoma kinase (ALK) gene in thyroid cancer.

148 Molecular testing is positive for an anaplastic lymphoma kinase (ALK) gene rearrangement usin

149 Anaplastic lymphoma kinase (ALK) gene rearrangements are

150 In 2007, scientists discovered that anaplastic lymphoma kinase (ALK) gene rearrangements are

151 dermal growth factor receptor (EGFR) gene or anaplastic lymphoma kinase (ALK) gene rearrangements.

152 (2;5)(p23;q35) translocation which fuses the Anaplastic Lymphoma Kinase (ALK) gene with the Nucleopho

153 Aberrant activation of anaplastic lymphoma kinase (ALK) has been described in a

154 Analogues structurally related to anaplastic lymphoma kinase (ALK) inhibitor 1 were optimi

155 Ceritinib is a next-generation anaplastic lymphoma kinase (ALK) inhibitor, which has sh

156 Most anaplastic lymphoma kinase (ALK) inhibitors adopt a type

157 lending impetus to the development of novel anaplastic lymphoma kinase (ALK) inhibitors with differe

158 naene macrocycles were prepared as potential anaplastic lymphoma kinase (ALK) inhibitors, designed to

159 Anaplastic lymphoma kinase (ALK) is a promising therapeu

160 Anaplastic lymphoma kinase (ALK) is a receptor tyrosine

161 Anaplastic lymphoma kinase (ALK) is a receptor tyrosine

162 Anaplastic lymphoma kinase (ALK) is a receptor tyrosine

163 Anaplastic lymphoma kinase (Alk) is a receptor tyrosine

164 Anaplastic lymphoma kinase (ALK) is a receptor tyrosine

165 The anaplastic lymphoma kinase (ALK) is chromosomally rearra

166 The orphan receptor anaplastic lymphoma kinase (ALK) is one of very few RTKs

167 MYCN overexpression combined with activated anaplastic lymphoma kinase (ALK) is sufficient to induce

168 Anaplastic lymphoma kinase (ALK) mutations occur in 3% t

169 malignant transformation of T cells that are anaplastic lymphoma kinase (ALK) negative and CD30 posit

170 The metabolic shift is mediated through the anaplastic lymphoma kinase (ALK) phosphorylation of the

171 The aim of this study is to investigate anaplastic lymphoma kinase (ALK) protein expression and

172 Crizotinib (1), an anaplastic lymphoma kinase (ALK) receptor tyrosine kinas

173 Here we report a novel isoform of the anaplastic lymphoma kinase (ALK) that is expressed in ap

174 aim of the present review is to describe the anaplastic lymphoma kinase (ALK) translocation as a prom

175 sets of lung cancers with EGFR mutations and anaplastic lymphoma kinase (ALK) translocations.

176 h epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) tyrosine kinase inhibit

177 epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) tyrosine kinase inhibit

178 epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) tyrosine kinase inhibit

179 vered in many T-cell malignancies, including anaplastic lymphoma kinase (ALK)(-) anaplastic large cel

180 Genetic studies have established anaplastic lymphoma kinase (ALK), a cell surface recepto

181 a distinct role for one of the DMGs encoding anaplastic lymphoma kinase (ALK), an important regulator

182 se domain that is physiologically related to anaplastic lymphoma kinase (ALK), and is undergoing Phas

183 EGFR), rearranged during transfection (RET), anaplastic lymphoma kinase (ALK), and MAPK1/3 and other

184 ts in nonsmall cell lung cancer fuse EML4 to anaplastic lymphoma kinase (ALK), causing expression of

185 Anaplastic lymphoma kinase (ALK), EGF receptor (EGFR), a

186 otubule-associated protein like 4 (EML4) and anaplastic lymphoma kinase (ALK), generated by an invers

187 Crizotinib, an inhibitor of anaplastic lymphoma kinase (ALK), has also recently show

188 by R1-R6 axons interacts with its receptor, anaplastic lymphoma kinase (Alk), on budding dendrites t

189 Anaplastic lymphoma kinase (ALK), physiologically expres

190 genes encoding the receptor tyrosine kinases anaplastic lymphoma kinase (ALK), ROS proto-oncogene 1 (

191 ), human epidermal growth factor receptor 2, anaplastic lymphoma kinase (ALK), v-Raf murine sarcoma v

192 YCN cooperates with mutational activation of anaplastic lymphoma kinase (ALK), which promotes progres

193 absence of translocations that activate the anaplastic lymphoma kinase (ALK), with nucleophosmin-ALK

194 For comparison, CNAs for anaplastic lymphoma kinase (ALK)- nodal anaplastic large

195 ied, angioimmunoblastic T-cell lymphoma, and anaplastic lymphoma kinase (ALK)-negative anaplastic lar

196 Anaplastic lymphoma kinase (ALK)-negative anaplastic lar

197 orrelates with relapse risk in children with anaplastic lymphoma kinase (ALK)-positive anaplastic lar

198 a small subset of cells purified from human anaplastic lymphoma kinase (ALK)-positive and -negative,

199 ngioimmunoblastic T-cell lymphoma (AITL), 31 anaplastic lymphoma kinase (ALK)-positive and 48 ALK-neg

200 heterogeneous disease that includes systemic anaplastic lymphoma kinase (ALK)-positive and ALK-negati

201 h crizotinib demonstrates robust efficacy in anaplastic lymphoma kinase (ALK)-positive non-small-cell

202 In a patient who had metastatic anaplastic lymphoma kinase (ALK)-rearranged lung cancer,

203 cacy of ceritinib in patients with untreated anaplastic lymphoma kinase (ALK)-rearranged non-small-ce

204 Most patients with anaplastic lymphoma kinase (ALK)-rearranged or ROS proto

205 Resistance to anaplastic lymphoma kinase (ALK)-targeted therapy in ALK

206 eloped as potent and selective inhibitors of anaplastic lymphoma kinase (ALK).

207 somatic aberrations in the gene encoding for anaplastic lymphoma kinase (ALK).

208 noderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion protein is

209 utively active tyrosine kinase nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) expressing anaplast

210 h epidermal growth factor receptor [EGFR] or anaplastic lymphoma kinase [ALK] genetic alterations wer

211 he presence of a translocation involving the anaplastic lymphoma kinase ALK gene.

212 p studies, chromosomal rearrangements of the anaplastic lymphoma kinase gene (ALK) have been associat

213 xenograft models of the novel and selective anaplastic lymphoma kinase inhibitor 15b (LDK378) are de

214 ells that are sensitive and resistant to the anaplastic lymphoma kinase inhibitor alectinib.

215 microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase positive (ALK+) non-small-cel

216 assively parallel sequencing instrument, and anaplastic lymphoma kinase translocation was evaluated b

217 vity to epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors ha

218 accompanied by mutational activation of ALK (anaplastic lymphoma kinase), suggesting their pathogenic

219 es the fusion protein NPM-ALK (nucleophosmin-anaplastic lymphoma kinase).

220 , we determined that the Midkine-a receptor, anaplastic lymphoma kinase, is upstream of the HLH regul

221 cell lymphoma (BIA-ALCL) is a CD30-positive, anaplastic lymphoma kinase-negative T-cell lymphoma.

222 Using conditional transgenic models of anaplastic lymphoma kinase-positive (ALK(+)) lymphomas a

223 Anaplastic lymphoma kinase-positive (ALK+) ALCL is assoc

224 In anaplastic lymphoma kinase-positive (ALK+) ALCL, WASP an

225 Anaplastic lymphoma kinase-positive (ALK-positive) disea

226 Using nucleophosmin-anaplastic lymphoma kinase-positive (NPM-ALK(+)) anaplas

227 sociated T-cell lymphoma patients (excluding anaplastic lymphoma kinase-positive anaplastic large cel

228 d in a caspase-dependent manner in apoptotic anaplastic lymphoma kinase-positive, anaplastic large ce

229 cancers harbor fusions in the gene encoding anaplastic lymphoma receptor tyrosine kinase (ALK), but

230 ts; and breast implant-associated large cell anaplastic lymphoma.

231 rotein, NIPA (Nuclear Interacting Partner of Anaplastic Lyphoma Kinase) is linked to a protection fro

232 classic medulloblastoma (CMB) or large-cell/anaplastic medulloblastoma (LCA).

233 esmoplastic/nodular and 45.97 for large-cell/anaplastic medulloblastoma) and nonresponse to the first

234 SK were significantly higher in atypical and anaplastic meningiomas than in typical meningiomas (P<.0

235 Medulloblastomas that display a large cell/anaplastic morphology and overexpress the cellular c-MYC

236 55) and 40% (95% CI, 0 to 83) for large-cell/anaplastic (n = 5) medulloblastoma ( P < .001 for EFS; P

237 tic oligodendrogliomas, pure (AO) and mixed (anaplastic oligoastrocytoma [AOA]), are chemosensitive,

238 c astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, and brain neoplasm.

239 Adult patients with newly diagnosed anaplastic oligodendroglial tumors were randomly assigne

240 Patients with 1p/19q codeleted anaplastic oligodendroglial tumors who participated in R

241 stine, and vincristine (PCV) chemotherapy in anaplastic oligodendroglial tumors.

242 r 59.4 Gy of RT increases both OS and PFS in anaplastic oligodendroglial tumors.

243 Anaplastic oligodendroglioma (AO) are rare primary brain

244 Anaplastic oligodendroglioma are chemotherapy-sensitive

245 Today, the diagnosis of anaplastic oligodendroglioma requires the presence of bo

246 a, malignant glioma, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytom

247 de glioma were included: 10 glioblastomas, 1 anaplastic oligodendroglioma, and 1 anaplastic astrocyto

248 ing adult and paediatric glioblastoma (GBM), anaplastic oligodendroglioma, and diffuse intrinsic pont

249 Anaplastic oligodendrogliomas, pure (AO) and mixed (anap

250 er patients are easily treatable, those with anaplastic or poorly differentiated recurrent thyroid ca

251 Aggressive thyroid tumors (for example, anaplastic or poorly differentiated thyroid carcinoma) c

252 CD30+ anaplastic cells in primary cutaneous anaplastic T-cell lymphoma and large-cell transformed cu

253 nd G1 cell-cycle arrest in primary cutaneous anaplastic T-cell lymphoma cells in vitro and a xenograf

254 and antitumor immunity in primary cutaneous anaplastic T-cell lymphoma, and provide a rationale for

255 Primary cutaneous anaplastic T-cell lymphoma, characterized by the CD30+ a

256 toid papulosis (n = 9) and primary cutaneous anaplastic T-cell lymphomas (n = 2) responded; time to r

257 Although anaplastic TC (ATC) is rare among TCs, it is highly leth

258 in 97% of patients and poorly differentiated/anaplastic TC in 1.1%.

259 40x10(6)) and human granulocytes (CD56-) or anaplastic thyroid cancer (ARO) cells in the contralater

260 rly differentiated thyroid cancer (PDTC) and anaplastic thyroid cancer (ATC) are rare and frequently

261 Anaplastic thyroid cancer (ATC) is a rare malignancy tha

262 Background Anaplastic thyroid cancer (ATC) is aggressive with a poo

263 Anaplastic thyroid cancer (ATC) is one of the most aggre

264 Anaplastic thyroid cancer (ATC) is one of the most letha

265 cancer cell lines, 3 melanoma cell lines, 20 anaplastic thyroid cancer (ATC) tumors, and 23 melanoma

266 oma, non-small cell lung cancer (NSCLC), and anaplastic thyroid cancer (ATC), making BRAF a desirable

267 Anaplastic thyroid cancer (ATC), one of the most aggress

268 mice with characteristic cell morphology of anaplastic thyroid cancer (ATC).

269 Functional investigations using the anaplastic thyroid cancer cell line CAL-62 found that si

270 and how interactions between fibroblasts and anaplastic thyroid cancer cells contribute to thyroid ca

271 n contact with soluble factors secreted from anaplastic thyroid cancer cells, compared to the fibrobl

272 ures by using transwells as well as by using anaplastic thyroid cancer cells-derived conditioned medi

273 ved for treatment of metastatic melanoma and anaplastic thyroid cancer in patients with confirmed BRA

274 Anaplastic thyroid cancer is an aggressive and highly le

275 Anaplastic thyroid cancer is one of the most aggressive

276 PURPOSE OF REVIEW: Anaplastic thyroid cancer is the most aggressive solid t

277 d two clonal spheroid CSC lines derived from anaplastic thyroid cancer that were even more enriched w

278 patients with pleomorphic xanthoastrocytoma, anaplastic thyroid cancer, cholangiocarcinoma, salivary-

279 Conclusion In a mouse model of anaplastic thyroid cancer, ferumoxytol MRI showed 136% +

280 ments in normal animals and murine models of anaplastic thyroid cancer, glioblastoma, and triple-nega

281 and expressed at highest levels in PDTC and anaplastic thyroid cancer.

282 ist for patients with advanced papillary and anaplastic thyroid cancer.

283 p75(NTR) was overexpressed in anaplastic thyroid cancers compared with papillary and f

284 Our study showed that anaplastic thyroid cancers had significantly more CSCs t

285 ge series of human poorly differentiated and anaplastic thyroid cancers screened by next-generation s

286 gher prevalence in poorly differentiated and anaplastic thyroid cancers, and it did not overlap with

287 RET and BRAF in patients with medullary and anaplastic thyroid cancers, respectively.

288 rum of dedifferentiation from classic PTC to anaplastic thyroid cancers.

289 ct of the proteasome inhibitor bortezomib on anaplastic thyroid carcinoma (ATC) characterized by comp

290 Anaplastic thyroid carcinoma (ATC) has among the worst p

291 Anaplastic thyroid carcinoma (ATC) is a frequently letha

292 Anaplastic thyroid carcinoma (ATC) is one of the most le

293 Anaplastic thyroid carcinoma (ATC) is refractory to radi

294 tance developed in a patient with metastatic anaplastic thyroid carcinoma after an extraordinary 18-m

295 ents with locally advanced and/or metastatic anaplastic thyroid carcinoma in a phase II cohort of the

296 Anaplastic thyroid carcinoma is an aggressive malignancy

297 rst clinical trial to show responsiveness of anaplastic thyroid carcinoma to PD-1 blockade.

298 anced/metastatic solid tumors, patients with anaplastic thyroid carcinoma were treated with spartaliz

299 45 total WTPDX, 6 from patients with diffuse anaplastic tumors, 9 from patients who experienced disea

300 VI) in patients with newly diagnosed diffuse anaplastic Wilms tumor (DAWT) and whether a regimen cont